Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems

Journal of Diabetes Science and Technology

Volumn 9, Issue 1, 2015, Pages 24-33

  Newswanger, Brett ^a   Ammons, Steve ^b   Phadnis, Neelima ^c   Kenneth Ward, W ^d   Castle, Jessica ^e   Campbell, Robert W ^a   Prestrelski, Steven J ^a  

^a Xeris Pharmaceuticals   (United States)

^b LEGACY RESEARCH   (United States)

^c Pacific Diabetes Technologies   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e Insulet Corporation   (United States)

Author keywords

glucagon; hypoglycemia; infusion; nonaqueous

Indexed keywords

DIMETHYL SULFOXIDE; GLUCAGON; GLUCOSE; NONAQUEOUS GLUCAGON; RECOMBINANT GLUCAGON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CELL DEATH; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; GLUCOSE BLOOD LEVEL; HIGH TEMPERATURE; HISTOPATHOLOGY; HUMAN; INSULIN PUMP; MALE; NONHUMAN; RABBIT MODEL; SKIN IRRITATION; STORAGE TEMPERATURE; WEIGHT CHANGE; YORKSHIRE PIG; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; INFUSION PUMP; PIG; RABBIT; SYNTHESIS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GLUCAGON; INFUSION PUMPS; MALE; RABBITS; SWINE;

EID: 84926347273     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814565131     Document Type: Article

References (10)

1. Eli Lilly and Co. Glucagon for injection (rDNA origin) prescribing information. Revised September 2012
2. Novo Nordisk, Inc. GlucaGen (glucagon [rDNA origin] for injection) prescribing information. Revised April 2014
3. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001;24(4):643-645
4. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33:1282-1287
5. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313-325
6. Cersosimo E, Cummins MJ, Kinzel JH, et al. A phase 2 comparative safety PK/PD study of stable nonaqueous glucagon (G-Pen) vs. Lilly glucagon for treatment of severe hypoglycemia. Diabetes Care. 2014;63(suppl 1A):LB1
7. Jiskoot W, Schellekens H, Crommelin DJA, Hermeling S. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. June 2004;21(6):897-903
8. Cooper AM, Braatvedt GD, Qamar MI, et al. Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man. Clin Sci (Lond). 1991;81(2):169-175
9. Halter JB, Pflug AE. Effects of anesthesia and surgical stress on insulin secretion in man. Metabolism. 1980;29(11 suppl 1): 1124-1127
10. Halter JB, Pflug AE. Relationship of impaired insulin secretion during surgical stress to anesthesia and catecholamine release. J Clin Endocrinol Metab. 1980;51(5):1093-1098